Research & Development
Eli Lilly signs Joint Procurement Agreement with European Commission to provide bamlanivimab and etesevimab to treat COVID-19
22 September 2021 -

Eli Lilly and Company (NYSE: LLY), a US-based global health care company, announced on Tuesday that it has signed a Joint Procurement Agreement with the European Commission to provide up to 220,000 doses of bamlanivimab and etesevimab to treat confirmed COVID-19 in patients aged 12 years and older who do not need supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19.

The contract helps to provide access to treatments by allowing participating countries in the European Union and European Economic Area to buy the products directly from Lilly, subsequent to the national approval for emergency use, or marketing authorisation at the European Union level. Quantities purchased are likely to vary based on local requirements as determined by participating countries.

Preclinical data from the labs have indicated that bamlanivimab and etesevimab administered together retain neutralisation activity compared to COVID variants presently in circulation in various countries, including Delta and Alpha. Based on the high transmissibility of the Delta variant, presently more than 95% of new COVID-19 infections in the EU/EEA have been identified as being caused by the Delta variant.



Related Headlines